Obstructive Lung Disease

Cystic Fibrosis Updates in Care: Part II — The “Sweat Sticker” and Clinician Q&A

By

Tori Rodriguez, MA, LPC, AHC

Publish Date May 21, 2021

In honor of Cystic Fibrosis Awareness Month, we present a 2-part series on treatment updates in the field, including the “sweat sticker.”

Primary Ciliary Dyskinesia: Practical Pearls for Diagnosis

By

Suzanne Bujara

Publish Date January 28, 2019

Recent guidelines set forth by an interdisciplinary panel assembled by the American Thoracic Society sought to demystify primary ciliary dyskinesia and address 4 main diagnostic questions.

Is There an “Ideal” Cystic Fibrosis Candidate for Lung Transplantation?

By

Suzanne Bujara

Publish Date August 23, 2018

Lung transplantation can extend survival in patients with cystic fibrosis who have compromised lung function and increasing exacerbations.

Aging and Bronchiolitis Obliterans Syndrome Linked to More Interalveolar Pores

By

Bryant Moeller

Publish Date July 30, 2021

Investigators found that aging and bronchiolitis obliterans syndrome are both associated with increased interalveolar communications.

What Affects Prescription Adherence of Patients With Obstructive Lung Disease?

By

Sheila Jacobs

Publish Date July 8, 2021

This studied focused on primary prescription adherence for obstructive lung diseases among adult patients in primary care over a 3-year period.

Trikafta Approval Expanded to Include Younger Cystic Fibrosis Patients

By

Brian Park, PharmD

Publish Date June 17, 2021

The approval was based on data from a phase 3 study that evaluated Trikafta in 66 children 6 to 11 years of age with CF who were either homozygous for the F508del mutation or heterozygous for the F508del mutation and 1 minimal function mutation.

Assessing the Risk of SARS-CoV-2 Infection in Patients With Cystic Fibrosis

By

Rita Aghjayan

Publish Date June 9, 2021

While a subset of people with cystic fibrosis may experience a more severe clinical course of COVID-19, they are not at an increased risk of contracting SARS-CoV-2 compared with the general population.

Elexacaftor/Tezacaftor/Ivacaftor Improved Lung Function in Cystic Fibrosis

By

Bryant Moeller

Publish Date June 4, 2021

Combination therapy with elexacaftor/tezacaftor/ivacaftor resulted in clinically significant improvements in lung function in patients with cystic fibrosis.

Predictors of Failed Pseudomonas aeruginosa Eradication in Children With Cystic Fibrosis

By

Bradley van Paridon

Publish Date June 3, 2021

Investigators sought to determine whether resistance to antibiotic treatment was associated with failed eradication therapy in patients with cystic fibrosis.

Lumacaftor-Ivacaftor Safe, Effective for Long-Term Treatment of Cystic Fibrosis

By

Virginia A. Schad, PharmD, RPh

Publish Date May 20, 2021

Lumacaftor-ivacaftor is generally safe and well tolerated for long-term treatment of children with cystic fibrosis homozygous for the F508del-CFTR mutation.

Digital Tomosynthesis Effectively Estimates Structural Lung Disease in Cystic Fibrosis

By

Brandon May

Publish Date April 19, 2021

Digital tomosynthesis of the chest offers effective quantitative estimation of structural lung disease in patients with cystic fibrosis.